Background: High-risk and recurrent medulloblastoma (MB) is associated with significant mortality. The murine monoclonal antibody 3F8 targets the cell-surface disialoganglioside GD2 on MB.
INTRODUCTION
Few curative treatment options exist for recurrent medulloblastoma (MB). Some studies support a role for high-dose chemotherapy with autologous hematopoietic cell rescue, although cure for patients with previously irradiated recurrent MB is unlikely. [1] [2] [3] Direct intrathecal delivery of radiolabeled tumor-specific antibodies or peptides may aid in both detection and treatment of recurrent leptomeningeal disease. [4] [5] [6] [7] [8] [9] [10] [11] We previously described a murine monoclonal IgG3 antibody, 3F8, that recognizes disialoganglioside GD2, a tumor antigen homogeneously distributed on the cell membrane of solid tumors of neuroectodermal origin, including MB. [12] [13] [14] Gangliosides are cell membrane associated lipid-sugar compounds thought to influence a variety of cellular functions including those affecting tumorigenesis. 3F8 is nonreactive with most normal human tissues including bone marrow, colon, stomach, heart, lung, muscle, thyroid, testes, pancreas; expression is found on central neurons and peripheral nerves. Intravenous anti-GD2 therapy is standard of care for patients with metastatic neuroblastoma. 15, 16 3F8 radiolabeled with I-124 and I-131 retains its immunoreactive properties. 17, 18 Improvement in overall survival (OS) has been noted with the incorporation of compartmental intraventricular radioimmunotherapy (cRIT) including 131 I-labeled 3F8 for patients with relapsed central nervous system neuroblastoma. 19 We evaluated the efficacy, dosimetry, and toxicity of cRIT with 124 
PATIENTS AND METHODS
Study NCT00445965 is an open study available for adult and pediatric patients with GD2-expressing CNS malignancies including MB.
The primary aim of this study was to determine the OS of patients with MB following intra-Ommaya 131 I-3F8, to determine the response rate to 131 I-3F8 in this population, and secondarily, to determine the cumulative toxicities of serial injections of intra-Ommaya 131 I-3F8.
3F8 monoclonal antibody (MoAb)
MoAb 3F8 was purified at MSK. 124 I-3F8 and 131 I-3F8 radiolabeling and dose preparation were performed at the MSK Radiochemistry and Molecular Imaging Probe Core. For every patient dose, 2 mg of 3F8 were radiolabeled using the iodogen method. Every batch was quality control tested to assure conformance to the acceptance specifications detailed in an US Food and Drug Administration (FDA) acknowledged investigative new drug application. The total mass of 3F8 in both 2 mCi (where Ci is Curie) dosimetry doses and 10 mCi therapy doses was adjusted to approximately 2 mg with cold 3F8. 12,17,18
Eligibility
The subject of this analysis includes all patients with a histologically confirmed diagnosis of high-risk or recurrent MB or PNET. High-risk patients were those less than 3 years of age at diagnosis with nondesmoplastic histology and no history of radiation therapy or those with refractory M+ disease following radiation and chemotherapy.
Patients with high-risk disease who had residual disease after initial surgery, radiation therapy, and chemotherapy were also eligible for cRIT upfront prior to disease progression.
All other patients had recurrent MB following standard therapy.
Molecular grouping by WNT, SHH, or CMYC status was generally not performed. Patients demonstrated a normal or less than grade 3 kidney and liver profile, platelets >50,000/ l and absolute neutrophil count >1,000/ l. Prior focal or craniospinal radiation therapy was permitted, but not within 3 weeks prior to 3F8 injections.
Prior radiation limits were confined to less than 72 Gy (where Gy 
cRIT therapy
Pretreatment evaluation included a detailed history, physical examination, complete blood count, metabolic profile, liver function, and thyroid function tests. CSF from the indwelling Ommaya catheter was examined for total protein, glucose, cell count, and cytology. Patients had a magnetic resonance imaging (MRI) of the brain and spine with and without gadolinium within 3 weeks prior to the dosimetry injection. To minimize the uptake of radioiodine by the thyroid, patients were premedicated with oral saturated solution of potassium iodide drops and liothyronine starting 5-7 days prior to the first injection and continued for 2 weeks after the last injection. To prevent a possible allergic or meningitic reaction, patients received oral acetaminophen and diphenhydramine prior to each injection. Oral or intravenous dexamethasone 0.5-1 mg (twice daily for a total of six doses) was given with each injection. The dexamethasone was a flat dose (older patients or >20 kg received 1 mg). Ceftriaxone was given approximately 1 hr after each injection. 
Evaluation of response
Conventional MRI brain imaging included sagittal and axial T1- 
Dosimetry
Dosimetry to the CSF in the ventricles and within the thecal sac was determined by region-of-interest analysis 124 I-3F8/PET imaging or 131 I-3F8/SPECT gamma camera imaging obtained at approximately 4, 24, and 48 hr after injection of a 2 mCi administered activity as previously described. 4 124 I-3F8/PET was the preferred tracer but both availability and expense of 124 I-3F8/PET precluded its regular use, where 131 I-3F8/SPECT was always available at a significantly reduced cost. CSF and blood dosimetry was also concurrently estimated by corresponding samples obtained at the same time points postinjection and measured aliquots were radioassayed in a scintillation well counter calibrated for 124 I or 131 I. The pharmacokinetic data obtained from PET or gamma-camera imaging and CSF sampling were combined with anatomical imaging information to estimate the absorbed dose to brain, spinal cord, and blood as previously described. [20] [21] [22] Given the risk of radionecrosis in the setting of prior conventional craniospinal radiation therapy with cRIT was unknown, a conservative estimate for cumulative dosing was used, recognizing the general spinal cord tolerance limit is 45 Gy. To avoid the risk of radiation toxicity in patients who had prior craniospinal radiation, the administered activity (dose) was reduced to ensure that the CSF radiation dose delivered by 131 I-3F8 did not exceed 2,400 cGy as determined by CSF sampling and serial nuclear medicine scans. In such patients, the maximum cumulative dose allowed by cRIT therapy injections was 2,400 cGy to the CSF, thereby requiring a dose adjustment to avoid exceeding this maximum.
Patient and treatment characteristics were described using frequencies and percentage for categorical variables, and medians and ranges for continuous variables. OS was calculated from the time of first I-3F8 injection until death. Patients alive at last follow-up were censored. PFS was calculated from the time of first I-3F8 injection until progression or death. Patients alive and disease-free at last follow-up were censored. OS and PFS were graphically displayed using KaplanMeier plots, and median, 6-month, 1-year, and 5-year Kaplan-Meier survival estimates were provided. The relationship between OS and patient characteristics was assessed with univariate Cox proportional hazards regression. P-values less than 0.05 were considered statistically significant, and all analyses were performed using SAS 9.4 (The SAS Institute, Cary, NC). In total, 42 patients were evaluable. Patient demographics are presented in Table 1 . Changing stages prior to cRIT included M0 (n = 2), M2 (n = 5), M3 (n = 33), and M3/M4 (n = 2).
RESULTS

Forty
Response
One patient was removed from the study because of clinical deterioration prior to ever receiving a therapy injection of 131 I-3F8. Of 
Survival
By the end of follow-up, 27 patients had died with a median OS of (Fig. 2B) . Numbers represent frequencies with percentage in parentheses unless otherwise specified.
TA B L E 1
There was one death in a long-term survivor from second malignancy, an 8-year-old male who died of secondary glioblastoma multi- one patient has been receiving therapy for extraneural metastases.
Characteristics of long-term survivors can be found in Table 2 .
Age (hazard ratio 
Acute side effects of cRIT 131 I-3F8
A secondary aim of this study was assessment of acute and longterm toxicities. cRIT 3F8 was routinely administered in the outpatient setting, with supportive care provided throughout the day of each injection. Patients were treated awake at the bedside. There were no treatment-related deaths during the injection period or postinjection observation period. Adverse events were self-limited, occurring in the first several hours after injection, and most commonly after the first therapy injections were primarily limited by the maximum allowed by protocol, 4 or by dosimetry estimates such that 2,400 cGy to the CSF was delivered for patients with prior craniospinal radiation therapy.
There were no complications related to raised intracranial pressure, hemorrhage, or infection.
Long-term toxicities
There were no long-term toxicities directly attributed to cRIT 3F8.
We specifically note the absence of radionecrosis in any patient in this cohort, despite receiving prior conventional radiation therapy, and additional radiation therapy delivered by cRIT. However, among longterm survivors with a history of prior high-dose induction chemotherapy, +/− myeloablative regimens, craniospinal radiation therapy, and cRIT 3F8, toxicity included symptomatic Moyamoya syndrome (N = 1) and symptomatic small-vessel angiopathy (N = 1). One patient with Gorlin syndrome developed a meningioma, ovarian fibrothecoma, and basal cell carcinoma, all developing more than 6 years after cRIT.
Dosimetry
All patients had distribution of the cRIT 3F8 demonstrated throughout the thecal sac on serial nuclear scans through 48-hr postdosimetry injection, although some irregularity in distribution around cerebral convexities was seen in some patients. By CSF sampling, the median dose to the CSF was 47.9 cGy/mCi (14.8-207.6) and to the blood 1.6 cGy/mCi (0.1-9.2). The median total dose delivered to the CSF was PET scans were generally similar to those of CSF sampling, while that with 131 I-3F8 gamma camera imaging were generally higher, more so for ventricular doses than for spinal canal region ( Table 3 ). The protocol mandated CSF and blood sampling only after the first dose, but to see how reproducible dosimetry estimates were, there were nine patients who had additional blood and CSF tested after each therapy injection.
Among nine patients who had blood and CSF samples analyzed for all four 131 I-3F8 cRIT therapies, there was large variability for both blood (%SD = 30-169%) and CSF (%SD = 15-98%) dose estimates with sampling (Supplementary Table S1 ). It was observed that dosimetry did not seem to be dependent on disease status.
TA B L E 2 Clinical demographics for 15 survivors treated with cRIT
Patient no. Numbers represent frequencies with percentage in parentheses unless otherwise specified.
TA B L E 3 cRIT results in 42 patients
Characteristics
DISCUSSION
cRIT with intraventricular 131 I-3F8 appears safe with manageable acute adverse events, even in a very heavily pretreated patient population. Injections were routinely given in the outpatient setting, with supportive care treating anticipated acute toxicities. Although the doselimiting toxicity for most radioimmunotherapy trials is myelosuppression, the dosing employed in this study was not associated with severe myelosuppression. Antitumor effect is attributed to the direct effect of beta plus gamma irradiation from 131 I-emission, although it is plausible that antitumor cytotoxicity may be in part due to complement activation within the CSF space. Previous observations in patients treated with rituximab suggested the activation of complement C3 and C5b-9 in the CSF after intraventricular administration for recurrent CNS lymphoma. 23 Although preliminary data have shown that some young children with MB may be cured with chemotherapy alone, the poor survival results for patients with recurrent MB have been noted in many series. [1] [2] [3] [24] [25] [26] [27] [28] Given experience with targeted immunotherapy efficacy when used as consolidation in the setting of minimal residual disease, this trial allowed for patients to enter cRIT without radiographically evaluable disease. It is acknowledged, however, that because of this, it is not appropriate to compare efficacy directly to other studies that mandated evaluable disease. However, given the extended survival for this cohort of patients, which includes patients with highrisk disease that still had evidence of leptomeningeal tumor after upfront chemotherapy and radiation therapy, cRIT 131 I-3F8 is encouraging, particularly when noting the progression-free and OS rates for patients with relapsed MB in other series published to date (Table 4) .
Status at the time of cRIT was related to OS, where patients in near radiographic and cytologic remission were at a lower risk of death compared to patients with progressive or radiographically measurable disease. It is important to note that we did not find an association between dose and OS. This would suggest that current cRIT 131 I-3F8
dosing is adequate to improve survival. Eleven of 15 long-term survivors received cRIT in the setting of radiographic and cytologic remission and remained in radiographic and cytologic remission; the other 4 patients had minimal and unchanged persistent focal nodularity on MRI. However, at the 10 mCi therapy dose, there does not appear to be a benefit of GD2-directed cRIT 3F8 in the setting of bulky progressive MB. Given that the maximum CSF dose allowed on this study for patients with prior craniospinal radiation therapy was 2,400 cGy, it is possible that increasing the number of injections and total dose to the CSF may contribute to disease control for patients with measureable disease. Importantly, given the absence of radionecrosis in this study cohort, a dose escalation should be considered in future studies. 29 Although this was not a randomized comparison between second remission consolidation with or without cRIT, the prolonged TA B L E 4 Progression-free and overall survival rates for recurrent medulloblastoma in large series survival for patients receiving cRIT suggest a survival advantage compared to historical estimates. 24 An important aim of this study was to determine the doses deliv- Further studies may incorporate an analysis of GD2 expression with response and survival. In addition, patients with both classic MB and PNET were eligible for this study, so while recent data suggest that the tumors are not as related as once thought, all patients were included in this analysis. Moving forward, the distinction between MB and PNET will be made. Additional efforts are being made to subgroup patients prospectively, but at the time this trial accrued patients, this molecular subgroup analysis was not routinely undertaken. In the present era of molecular profiling of MB into distinct subtypes with prognostic implications, it is now possible to consider dose reduction of therapies with known neurocognitive risks such as CSI. The findings presented suggest that prolonged survival with cRIT treatment is possible in a subset of patients. Finally, we note that although this study used a MoAb targeting GD2, other tumor-associated antigens may similarly be exploited; we have developed another antibody 8H9 targeting B7-H3, also found to be highly overexpressed on MB and may also be considered for cRIT. 31 
CONCLUSIONS
Intraventricular radioimmunotherapy can be successfully incorporated into treatment strategies as consolidation for relapsed and highrisk MB. The role of cRIT in patients with bulky tumors at the current dosing levels is questionable. Future studies are warranted to evaluate feasibility of higher dosing or differentiate treatment strategies in those with bulky disease.
